AQST
Aquestive Therapeutics, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 72 | +3 | 39.01M | $162.27M | +5 | −2 |
| Q1 2026 | 71 | -4 | 39.34M | $163.45M | +7 | −11 |
| Q4 2025 | 75 | 0 | 41.69M | $269.29M | +1 | −1 |
| Q3 2025 | 16 | 0 | 21.57M | $120.55M | +1 | −1 |
| Q2 2025 | 13 | +1 | 18.15M | $60.07M | +1 | — |
| Q1 2025 | 9 | -2 | 4.86M | $14.09M | — | −2 |
| Q4 2024 | 11 | +1 | 4.40M | $15.68M | +1 | — |
| Q3 2024 | 9 | +1 | 3.11M | $15.51M | +2 | −1 |
| Q2 2024 | 8 | — | 2.58M | $6.65M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 1.58M | — | $4.10M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.58M | — | $4.10M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Renaissance Technologies ✦ | 496.20K | — | $1.29M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 167.81K | — | $436,314 | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Two Sigma Investments ✦ | 136.63K | — | $355,233 | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Millennium Management ✦ | 90.86K | — | $236,241 | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Marshall Wace ✦ | 77.02K | — | $200,242 | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Marshall Wace ✦ | 77.02K | — | $200,242 | 0.0% | n/c | 1 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 10.19K | — | $26,489 | 0.0% | n/c | 1 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 23.85K | — | $0 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 174 holders, 66.03M shares, $284.02M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 25.00K sh · $107,168
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology